Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling. - Archive ouverte HAL Access content directly
Journal Articles Science Translational Medicine Year : 2010

Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling.

(1) , (1, 2, 3, 4)
1
2
3
4

Abstract

The identification of one mechanism that causes vision loss in inherited degenerative retinal disorders revealed a new signaling molecule that represents a potential therapy for these currently untreatable diseases. This protein, called rod-derived cone viability factor (RdCVF), maintains the function and consequently the viability of cone photoreceptor cells in the retina; mice that lack this factor exhibit a progressive loss of photoreceptor cells. The gene encoding RdCVF also encodes, by differential splicing, a second product that has characteristics of a thioredoxin-like enzyme and protects both photoreceptor cells and, more specifically, its interacting protein partner, the tau protein, against oxidative damage. This signaling pathway potentially links environmental insults to an endogenous neuroprotective response.
Fichier principal
Vignette du fichier
inserm-00472434_edited.pdf (348.9 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-00472434 , version 1 (12-04-2010)

Identifiers

Cite

Thierry Léveillard, José-Alain Sahel. Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling.. Science Translational Medicine, 2010, 2 (26), 26ps16. ⟨10.1126/scitranslmed.3000866⟩. ⟨inserm-00472434⟩
140 View
612 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More